Table 6.

Potential concomitant medication interferences

Medium validation sample (1500 ng/mL) was spiked with potential concomitant drugs at 5000 ng/mL and processed as usual.

Drugs	Peak area ratio (INH/IS)				STD	%CV	%Dev due to matrix effect
	replicate 1	replicate 2	replicate 3	mean
control	3.64	3.74	3.67	3.68	0.05	1.35
EFV	3.64	3.44	3.68	3.59	0.13	3.55	-2.49
ZDV	3.62	3.51	3.55	3.56	0.05	1.52	-3.35
TFV	3.79	3.78	3.67	3.75	0.07	1.76	1.85
ATV	3.78	3.77	4.09	3.88	0.19	4.80	5.42
LPV	3.69	3.87	3.94	3.83	0.13	3.43	4.18
RTV	3.61	3.87	3.70	3.73	0.13	3.46	1.23
NFV	4.22	4.01	4.22	4.15	0.12	2.89	12.8
NVP	3.31	3.37	3.47	3.39	0.08	2.40	-7.98
IDV	3.93	3.87	3.88	3.89	0.03	0.89	5.82
APV	3.88	3.67	3.66	3.74	0.13	3.39	1.52
ABV	3.52	4.03	4.00	3.85	0.29	7.45	4.67
SQV	3.73	3.88	3.76	3.79	0.08	2.07	2.94